Skip to main content

Table 2 The patient’s demographics and patient’s seroprotection status

From: Antibody waning after immunosuppressive chemotherapy and immunomodulators, re-immunization considerations in pediatric patients with malignancy and chronic immune thrombocytopenic purpura

 

Seroprotection status (n, %)

Total

Partially protected

Fully susceptible*

Age category

 2 to 5 years

36 (64.3%)

20 (35.7%)

56

 5 to 10 years

38 (82.6%)

8 (17.4%)

46

 > 10 years

6 (75%)

2 (25%)

8

Total

80

30

110

  1. *Represents non-reactivity of all tested vaccine-type antibodies
  2. **Incidence risk